Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Blair William & Co. IL

Blair William & Co. IL lessened its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 70.8% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 26,644 shares of the pharmaceutical company's stock after selling 64,672 shares during the quarter. Blair William & Co. IL's holdings in Vertex Pharmaceuticals were worth $10,730,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Dunhill Financial LLC lifted its holdings in shares of Vertex Pharmaceuticals by 70.6% in the 3rd quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company's stock worth $27,000 after buying an additional 24 shares during the period. Brown Lisle Cummings Inc. bought a new stake in shares of Vertex Pharmaceuticals in the fourth quarter valued at about $30,000. Legacy Investment Solutions LLC purchased a new stake in Vertex Pharmaceuticals in the third quarter worth about $33,000. Sugar Maple Asset Management LLC bought a new position in Vertex Pharmaceuticals during the 4th quarter worth about $35,000. Finally, Golden State Wealth Management LLC purchased a new position in Vertex Pharmaceuticals during the 4th quarter valued at about $37,000. Hedge funds and other institutional investors own 90.96% of the company's stock.

Insider Activity at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 310 shares of Vertex Pharmaceuticals stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $459.83, for a total value of $142,547.30. Following the completion of the transaction, the executive vice president now owns 64,021 shares of the company's stock, valued at approximately $29,438,776.43. The trade was a 0.48 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP David Altshuler sold 3,231 shares of the stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $500.00, for a total transaction of $1,615,500.00. Following the sale, the executive vice president now directly owns 26,512 shares in the company, valued at approximately $13,256,000. The trade was a 10.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 4,315 shares of company stock worth $2,121,012. 0.20% of the stock is owned by corporate insiders.

Remove Ads

Analyst Ratings Changes

VRTX has been the topic of a number of recent research reports. Morgan Stanley increased their price objective on shares of Vertex Pharmaceuticals from $450.00 to $459.00 and gave the company an "equal weight" rating in a research note on Tuesday, February 11th. Jefferies Financial Group raised Vertex Pharmaceuticals from a "hold" rating to a "buy" rating and increased their target price for the company from $500.00 to $550.00 in a research report on Monday, December 9th. Oppenheimer lowered Vertex Pharmaceuticals from an "outperform" rating to a "market perform" rating in a research report on Thursday, December 19th. JPMorgan Chase & Co. dropped their price objective on Vertex Pharmaceuticals from $503.00 to $500.00 and set an "overweight" rating on the stock in a research report on Monday, December 23rd. Finally, Canaccord Genuity Group upgraded shares of Vertex Pharmaceuticals from a "sell" rating to a "hold" rating and raised their price target for the company from $408.00 to $424.00 in a report on Tuesday, February 11th. Ten research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Vertex Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $509.17.

Vertex Pharmaceuticals Stock Performance

Shares of NASDAQ:VRTX traded down $0.08 during midday trading on Tuesday, reaching $484.74. The company's stock had a trading volume of 1,249,029 shares, compared to its average volume of 1,279,226. The company has a quick ratio of 2.35, a current ratio of 2.69 and a debt-to-equity ratio of 0.01. The stock has a fifty day moving average of $477.71 and a 200 day moving average of $463.68. Vertex Pharmaceuticals Incorporated has a twelve month low of $377.85 and a twelve month high of $519.88. The firm has a market capitalization of $124.48 billion, a PE ratio of -220.34, a P/E/G ratio of 2.11 and a beta of 0.41.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its quarterly earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share for the quarter, missing the consensus estimate of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. On average, equities analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.